维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

10篇 您的检索式：作者名="Tetsunari"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Ovarian hormone receptors in human mammary stromal cells显示文摘	Frederick Koerner Tetsunari Oyama Masafumi Kurosumi Horacio Maluf	2001	Journal of Steroid Biochemistry and Molecular Biology2001，，：	1
	2	Expressionstatus of p16 proteinisas sociated with human papilloma virus oncogenic potential in cervical and genitallesions 显示文摘	Takaaki S Tetsunari O Kenji K	1998	Am J Pathol1998，153，9：	1
	3	Expression Status of p16 Protein Is Associated with Human Papillomavirus Oncogenic Potential in Cervical and Genital Lesions显示文摘	Takaaki Sano Tetsunari Oyama Kenji Kashiwabara Toshio Fukuda Takashi Nakajima	1998	The American Journal of Pathology1998，，6：	1
	4	expressin statuus of p16 poprotein is associated with human papillomavirus oneogenic potential ineervieal and gential earvinoma显示文摘	Takaaki S Tetsunari O Kenji	1998	Am J Pathol1998，，153：	1
	5	Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions显示文摘	Takaaki Sano Tetsunari Oyama Kenji Kashiwabara	1998	Am J Pathol1998，153，：	1
	6	Core needle biopsy (CNB) as a diagnostic method for breast lesions: Comparison with fine needle aspiration cytology (FNA)显示文摘	Tetsunari Oyama Yukio Koibuchi Grace McKee	2004	Breast Cancer2004，，4：	1
	7	Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions显示文摘	Takaaki S Tetsunari O Kenji K	1998	Am J Pathol1998，153，9：	1
	8	Large cell neuroendocrine carcinoma of the lung:a comparison with large cell carcinoma with neuroendocrine morphology and small cell carcinoma显示文摘	Peng WX Takaaki S Tetsunari O	2005	Lung Cancer2005，47，2：	1
	9	Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival显示文摘BACKGROUND Despite the popularity of immune checkpoint inhibitors(ICIs)in the treatment of advanced cancer,patients often develop gastrointestinal(GI)and non-GI immune-related adverse events(irAEs).The clinical characteristics and survival outcomes of GI-irAEs have not been fully elucidated in previous reports.This necessitates the evaluation of the impact of GI-irAEs on patients receiving ICI treatment.AIM To evaluate the clinical characteristics of GI-irAEs and their impact on survival in patients treated with ICIs.METHODS In this single-center,retrospective,observational study,we reviewed the records of 661 patients who received ICIs for various cancers at Nagoya University Hospital from September 2014 to August 2020.We analyzed the clinical characteristics of patients who received ICI treatment.We also evaluated the correlation between GI-irAE development and prognosis in non-small cell lung cancer(LC)and malignant melanoma(MM).Kaplan-Meier analysis was used to compare the median overall survival(OS).Multivariate Cox proportional hazards models were used to identify prognostic factors.A P value<0.05 was considered statistically significant.RESULTS GI-irAEs occurred in 34 of 605 patients(5.6%)treated with an anti-programmed cell death-1/programmed death-ligand 1(anti-PD-1/PD-L1)antibody alone and in nine of 56 patients(16.1%)treated with an anti-cytotoxic T-lymphocyte antigen 4(CTLA-4)antibody alone or a combination of anti-PD-1 and anti-CTLA-4 antibodies.The cumulative incidence and median daily diarrhea frequency were significantly higher in patients receiving anti-CTLA-4 antibodies(P<0.05).In 130 patients with MM,OS was significantly prolonged in the group that continued ICI treatment despite the development of GI-irAEs compared to the group that did not experience GI-irAEs(P=0.035).In contrast,in 209 patients with non-small cell LC,there was no significant difference in OS between the groups.The multivariate analyses showed that a performance status of 2-3(hazard ratio:2.406;95%confidence interval:1.125–5.147;P=0.024)was an independent predictive factor for OS in patients with MM.CONCLUSION Patients receiving anti-CTLA-4 antibodies develop GI-irAEs more frequently and with higher severity than those receiving anti-PD-1/PD-L1 antibodies.Continuing ICI treatment in patients with MM with GI-irAEs have better OS.	Kentaro Yamada Tsunaki Sawada Masanao Nakamura Takeshi Yamamura Keiko Maeda Eri Ishikawa Tadashi Iida Yasuyuki Mizutani Naomi Kakushima Takuya Ishikawa Kazuhiro Furukawa Eizaburo Ohno Takashi Honda Hiroki Kawashima Masatoshi Ishigami Satoshi Furune Tetsunari Hase Kenji Yokota Osamu Maeda Naozumi Hashimoto Masashi Akiyama Yuichi Ando Mitsuhiro Fujishiro	2021	World Journal of Gastroenterology2021，27，41：	0
	10	Double immunostaining of p63 and low - molecular-weight cytokeratin in pleomorphic adenomas显示文摘	Masahiro Wato Ayako Kawanaka Kazuya Tominaga Tetsunari Nishikawa Akio Tanaka	2008	中国口腔颌面外科杂志2008，6，B05：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费